Fichtner I - Search Results

1

In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.

Fichtner I, Becker M, Zeisig R, Sommer A. Fichtner I, et al. Eur J Cancer. 2004 Apr;40(6):845-51. doi: 10.1016/j.ejca.2003.11.030. Eur J Cancer. 2004. PMID: 15120040 Review.

2

Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo.

Zeisig R, Rückerl D, Fichtner I. Zeisig R, et al. Among authors: fichtner i. Anticancer Drugs. 2004 Aug;15(7):707-14. doi: 10.1097/01.cad.0000136885.65293.e9. Anticancer Drugs. 2004. PMID: 15269602

3

Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.

Becker M, Sommer A, Krätzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Becker M, et al. Among authors: fichtner i. Mol Cancer Ther. 2005 Jan;4(1):151-68. Mol Cancer Ther. 2005. PMID: 15657362

4

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft.

Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, Büttner B, Fichtner I. Naundorf H, et al. Among authors: fichtner i. Br J Cancer. 2000 Jun;82(11):1844-50. doi: 10.1054/bjoc.2000.1156. Br J Cancer. 2000. PMID: 10839300 Free PMC article.

5

Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).

Fichtner I, Becker M, Baumgart J. Fichtner I, et al. Eur J Cancer. 2003 Apr;39(6):801-7. doi: 10.1016/s0959-8049(02)00767-0. Eur J Cancer. 2003. PMID: 12651206

6

Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.

Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, Bibby M. Fichtner I, et al. Eur J Cancer. 2004 Jan;40(2):298-307. doi: 10.1016/j.ejca.2003.10.011. Eur J Cancer. 2004. PMID: 14728946

7

Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro.

Zeisig R, Teppke AD, Behrens D, Fichtner I. Zeisig R, et al. Among authors: fichtner i. Breast Cancer Res Treat. 2004 Oct;87(3):245-54. doi: 10.1007/s10549-004-8699-6. Breast Cancer Res Treat. 2004. PMID: 15528967

8

Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.

Wenzel J, Zeisig R, Haider W, Habedank S, Fichtner I. Wenzel J, et al. Among authors: fichtner i. Breast Cancer Res Treat. 2010 May;121(1):13-22. doi: 10.1007/s10549-009-0448-4. Epub 2009 Jun 23. Breast Cancer Res Treat. 2010. PMID: 19548083

9

Animal experiments-an essential component for the development of liposomal anticancer agents.

Fichtner I, Reszka R, Arndt D, Zeisig R. Fichtner I, et al. J Liposome Res. 2003 Feb;13(1):9-15. doi: 10.1081/lpr-120017483. J Liposome Res. 2003. PMID: 12725721 Review. No abstract available.

10

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Fichtner I, et al. Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138. Clin Cancer Res. 2008. PMID: 18927285 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters